Textbook of Psoriasis, Second Edition

Cover Page......Page 1
Title Page......Page 3
ISBN 1405107170......Page 4
Part 3: Therapy......Page 5
Contributors......Page 7
Preface......Page 9
1.1 Introduction......Page 12
1.2 Erythematosquamous manifestations of psoriasis......Page 14
1.3 Pustular manifestations of psoriasis......Page 23
1.4 Psoriasis of the nails......Page 27
1.5 Associated dermatoses......Page 28
1.6 Associated internal diseases......Page 30
1.7 Differential diagnosis......Page 31
References......Page 34
2.2 Epidemiology......Page 39
2.4 Aetiology and pathogenesis......Page 40
2.5 Clinical features......Page 41
2.7 Imaging techniques......Page 43
2.8 Differential diagnosis......Page 45
2.10 Management and treatment......Page 46
2.11 Summary......Page 49
References......Page 50
3.2 Quality of life in psoriasis......Page 52
3.3 Some psychosocial effects of psoriasis......Page 54
3.4 Patients’ views about psoriasis and its treatment......Page 56
3.5 The effects of stress on psoriasis......Page 57
3.8 Practical applications in the clinic......Page 59
References......Page 60
4.1 Descriptive epidemiology: assessment of morbidity......Page 66
4.2 Genetic epidemiology: analysis of inheritance and definition of disease subsets......Page 70
4.3 Investigative epidemiology: environmental risk factors......Page 71
References......Page 74
5.2 Population-based and family studies......Page 79
5.3 Recessive or dominant genes?......Page 81
5.4 Preferential paternal inheritance......Page 82
5.5 HLA associations and the PSORS1 locus......Page 84
5.6 Minor psoriasis susceptibility loci......Page 85
5.7 Biological candidate genes remain uncertain......Page 87
5.8 Conclusion......Page 88
References......Page 89
6.2 Systemic factors......Page 92
6.3 Cutaneous inflammation and stroma......Page 94
6.4 Proliferation and differentiation of keratinocytes......Page 97
6.5 The transition between symptomless and clinically involved skin......Page 104
6.6 Signal transduction pathways in epidermal proliferation and cutaneous inflammation......Page 106
6.7 Conclusions......Page 111
References......Page 112
7.2 T cells in psoriatic lesions......Page 119
7.3 Antigen-presenting cells in psoriasis......Page 120
7.4 T cell and antigen-presenting cell interaction......Page 121
7.5 Nuclear factor of activated T cells (NFAT) activation pathway and ciclosporin/FK-506/pimecrolimus......Page 122
7.6 The human interleukin 2 gene promoter......Page 124
7.8 Pharmacological evidence for psoriasis as an immunological disease......Page 125
References......Page 128
8.2 Vitamin D receptors: molecular mechanisms......Page 136
8.3 Biological actions of 1,25(OH)2D3 and vitamin D3 analogues......Page 137
8.5 Vitamin D metabolism in psoriasis......Page 139
8.6 Clinical effects of vitamin D3 and vitamin D3 analogues in psoriasis......Page 140
8.7 Conclusions......Page 155
References......Page 156
9.2 Background and pharmacology......Page 164
9.3 Mechanism of action......Page 165
9.4 Topical corticosteroids......Page 166
9.5 Systemic corticosteroids......Page 174
References......Page 175
10.2 History......Page 179
10.3 Chemistry, mode of action and pharmacology......Page 180
10.4 Indications and contraindications......Page 184
10.5 Side-effects......Page 185
10.6 Clinical effectiveness......Page 188
10.7 Combination treatment......Page 189
10.8 Guidelines for treatment......Page 192
References......Page 194
11.2 311-nm UVB: the phototherapy of choice for psoriasis......Page 200
11.3 PUVA therapy for psoriasis......Page 203
11.4 Photocarcinogenic risk of photo(chemo)therapy......Page 205
11.5 Mode of action of photo(chemo)therapy......Page 206
11.6 Combination therapy......Page 208
References......Page 211
12.1 Introduction......Page 217
12.2 Pharmacology and pharmacodynamics......Page 218
12.3 Results of methotrexate therapy......Page 222
12.4 Side-effects......Page 224
12.5 Methotrexate and the liver......Page 229
12.6 Guidelines for methotrexate therapy......Page 239
12.7 Combination therapy......Page 244
References......Page 248
13.1 Historical background......Page 256
13.2 Mechanisms of action......Page 259
13.3 Pharmacokinetics......Page 263
13.4 Clinical use......Page 265
13.5 Side-effects and interactions......Page 276
13.7 Contraindications......Page 278
References......Page 279
14.1 Introduction......Page 284
14.2 Ciclosporin......Page 286
14.3 Tacrolimus (FK506)......Page 295
14.5 Sirolimus (rapamycin)......Page 296
References......Page 297
15.1. Introduction......Page 302
15.2 T-cell-targeted therapies......Page 307
15.3 Cytokine-targeted therapies......Page 312
15.4 Miscellaneous......Page 314
15.5 Conclusion......Page 315
References......Page 316
16.1 Introduction......Page 320
16.2 A review of clinical use......Page 321
16.4 Review of clinical studies......Page 322
16.5 Adverse events related to FAE treatment......Page 323
16.6 Immunohistological investigations......Page 327
16.7 Outlook......Page 332
References......Page 333
17.1 Comparisons......Page 336
17.2 Combinations......Page 340
References......Page 343
B......Page 346
C......Page 347
D......Page 348
F......Page 349
I......Page 350
L......Page 351
N......Page 352
P......Page 353
Q,R......Page 354
S......Page 355
T......Page 356
U,V,W......Page 357
Color Plates......Page 358
Back Page......Page 363